A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

Phase 1 Completed 25 enrolled Phathom Pharmaceuticals, Inc.

RandomizedCrossoverOpen-labelBasic science

Summary

The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and administered via a syringe relative to the vonoprazan tablet in healthy participants.

Timeline

Start: 2025-02-14
Primary completion: 2025-04-05
Completion: 2025-04-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vonoprazan	Other / unclassified	10 mg	Oral

Indications

No indication recorded.